Randomised controlled trial of early versus late ureteric stent removal post kidney transplant

A single centre, open label, randomised controlled study to compare the incidence of urinary tract infections and urological complications among renal transplant recipients who have a ureteric stent removed 6-8 days versus 4-6 weeks post renal transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51276329

Enrollment

350

Registered

2014-12-12

Start date

2014-11-01

Completion date

Unknown

Last updated

2015-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological complications following renal transplantation Urological and Genital Diseases

Interventions

Group A - Removal of ureteric stent on day 6-8 post renal transplantation Group B - Removal of ureteric stent during week 4-6 post renal transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects freely giving their consent 2. Adult recipients of a kidney transplant from a living donor or a deceased donor (donation after brain death [DBD] or donation after circulatory death [DCD])

Exclusion criteria

Exclusion criteria: 1. Multi-organ transplant recipients such as heart-kidney, liver-kidney and small bowel-kidney transplants (but not simultaneous pancreas-kidney [SPK] transplants). 2. Renal transplant recipients in whom the donor ureter is not anastomosed to the recipient bladder (e.g., anastomosed onto the native ureter or an ileal conduit) 3. Recipients of double kidney transplants 4. Recipients of kidneys with two ureters

Design outcomes

Primary

Measure	Time frame
Composite of incidence of UTI and ureteric complications (urine leaks or ureteric stenosis)	—

Secondary

Measure	Time frame
1. Incidence of UTIs (symptomatic and asymptomatic bacteriuria considered separately) 2. Incidence of urine leak 3. Incidence of ureteric stenosis 4. Patient death 5. Graft loss 6. Surgical complications (renal vein thrombosis, renal artery thrombosis, bleeding, lymphocoele, wound infection, re-operation, urinary retention) 7. Immunological complications (delayed graft function, rejection) 8. Re-admission and duration of inpatient stay 9. Medical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, new onset diabetes after transplantation [NODAT]) All outcomes (primary and secondary) will be measured at 3 months post transplantation. The outcomes include rates of complications (e.g., urine leak, ureteric stenosis and urinary tract infections). All data will be obtained from a prospectively maintained database and the diagnosis of these complications will be based on standard clinical criteria.	—

Measure

Time frame

1. Incidence of UTIs (symptomatic and asymptomatic bacteriuria considered separately) 2. Incidence of urine leak 3. Incidence of ureteric stenosis 4. Patient death 5. Graft loss 6. Surgical complications (renal vein thrombosis, renal artery thrombosis, bleeding, lymphocoele, wound infection, re-operation, urinary retention) 7. Immunological complications (delayed graft function, rejection) 8. Re-admission and duration of inpatient stay 9. Medical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, new onset diabetes after transplantation [NODAT]) All outcomes (primary and secondary) will be measured at 3 months post transplantation. The outcomes include rates of complications (e.g., urine leak, ureteric stenosis and urinary tract infections). All data will be obtained from a prospectively maintained database and the diagnosis of these complications will be based on standard clinical criteria.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026